Boston Scientific’s Dual-Drug Stent Strategy Yields 50% Market Share In Q1
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific achieved a 50% share of the U.S. drug-eluting stent market in the first quarter on the strength of its Taxus and Promus systems - up three points from the final quarter of 2008, according to the company
You may also be interested in...
Research In Brief
Medifocus: Vancouver company files a response to FDA's questions on its investigation device exemption application for a pivotal trial of its Microfocus APA 1000 system for the treatment of breast cancer. The application was submitted in Jun,e and FDA's letter was received July 13. The 238-patient pivotal clinical trial will assess the safety and efficacy of focused microwave heat energy delivered by the Microfocus APA 1000 in combination with neo-adjuvant chemotherapy on large breast cancer tumors as measured by tumor shrinkage. A Phase II multicenter randomized study of Microfocus APA 1000 showed that the median tumor shrinkage in the thermo-chemo arm was about 88% compared to about 59% for chemotherapy alone. Almost 80% of all breast tumors treated with Microfocus APA 1000 got substantially smaller versus 20% in the chemotherapy group
Research In Brief
Medifocus: Vancouver company files a response to FDA's questions on its investigation device exemption application for a pivotal trial of its Microfocus APA 1000 system for the treatment of breast cancer. The application was submitted in Jun,e and FDA's letter was received July 13. The 238-patient pivotal clinical trial will assess the safety and efficacy of focused microwave heat energy delivered by the Microfocus APA 1000 in combination with neo-adjuvant chemotherapy on large breast cancer tumors as measured by tumor shrinkage. A Phase II multicenter randomized study of Microfocus APA 1000 showed that the median tumor shrinkage in the thermo-chemo arm was about 88% compared to about 59% for chemotherapy alone. Almost 80% of all breast tumors treated with Microfocus APA 1000 got substantially smaller versus 20% in the chemotherapy group
Research In Brief
Cook Spectrum: Cook's minocycline/rifampin-impregnated Spectrum central venous catheter is nearly twice as effective at preventing catheter-related bloodstream infections as catheters coated with chlorhexidine and silver sulfadiazine, according to results of a 46-month, head-to-head study presented by Craig Coopersmith, Washington University in St. Louis, at the Society of Critical Care Medicine's Critical Care Congress in Nashville on Feb. 2. Results of a separate study, presented at the meeting by Spectrum's inventor, Issam Raad, University of Texas, showed that exchanging an infected central venous catheter for a Spectrum can quickly eliminate the existing infection in cancer patients. In the trial, 40 patients with infected central venous catheters had their catheters exchanged for the Spectrum, and 80 patients simply had their infected catheters removed. 95% of patients receiving the Spectrum had no bacteremia within 72 hours with no cases of relapse or infection-related death. By comparison, 88% of patients whose catheters were simply removed had no bacteremia within 72 hours, and there were six cases of relapse or infection-related death in the catheter-removal group